Document is current
Any future updates will be listed below
-
Authors
Arab, Fahimeh Lavi
Yousefi, Forouzan
Naderi-Meshkin, Hojjat
Mirahmadi, Mahdi
Faraji, Fatemeh
Nikkhah, Karim
Amiri, Houshang
Erfani, Marjan
Ayoobi, Fatemeh
Tabasi, Nafiseh Sadat
Nikkhah, Ali
Mahmoudi, Mahmoud
-
Clinical Trials BETA
Clinical trials referenced in this document:
irct20091127002778n1 at Iranian Registry of Clinical TrialsDocuments that mention this clinical trial
Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I/IIa clinical results
https://doi.org/10.1186/s13287-026-04933-6
-
Funding
Funding for this research was provided by:
Mashhad University of Medical Sciences (921082)
- License Information
-
More Information
Article History
Received: 29 September 2025
Accepted: 2 February 2026
First Online: 22 February 2026
Declarations
:
: This study, entitled “ Study of autologous adipose-derived mesenchymal stem cells transplantation in the treatment of multiple sclerosis in secondary progressive phase, ” was approved by the Ethics Committee of Mashhad University of Medical Sciences, Mashhad, Iran (IR.MUMS.REC.1394.633; Date of approval: August 20, 2015). The study was conducted in accordance with the Declaration of Helsinki. All patients or their representatives signed written informed consent forms before participation. Additionally, the clinical trial was registered in the Iranian Registry of Clinical Trials (Reference: IRCT20091127002778N1 at October 1, 2018).
: All patients provided written informed consent for publication of their data.
: The authors declare no competing interests.
